Halving time of BCR-ABL1 in Chronic Myeloid Leukemia, Is it a better bet than day 90 value – Multicenter study from south India

ConclusionHalving time of BCR-ABL1appears promising in prediction of outcome in CML

Source: Clinical Lymphoma Myeloma and Leukemia - October 1, 2019 Category: Cancer & Oncology Source Type: research